RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of RAPT Therapeutics in a research report issued on Thursday, May 22nd. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.08) per share for the quarter. HC Wainwright has a "Strong-Buy" rating and a $6.00 price target on the stock. The consensus estimate for RAPT Therapeutics' current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for RAPT Therapeutics' Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.60) EPS and FY2029 earnings at ($0.74) EPS.
A number of other research analysts also recently weighed in on the company. UBS Group cut their price target on RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Wall Street Zen upgraded RAPT Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, RAPT Therapeutics has an average rating of "Hold" and a consensus price target of $3.00.
Check Out Our Latest Stock Analysis on RAPT
RAPT Therapeutics Price Performance
Shares of RAPT stock traded down $0.00 during trading hours on Monday, reaching $0.97. The company had a trading volume of 1,034,926 shares, compared to its average volume of 1,284,948. The company has a 50 day moving average of $0.98 and a 200 day moving average of $1.14. The firm has a market cap of $128.70 million, a price-to-earnings ratio of -0.35 and a beta of -0.04. RAPT Therapeutics has a 1-year low of $0.71 and a 1-year high of $4.60.
RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.23.
Hedge Funds Weigh In On RAPT Therapeutics
Several hedge funds have recently modified their holdings of RAPT. Medicxi Ventures Management Jersey Ltd bought a new position in RAPT Therapeutics during the fourth quarter worth about $35,316,000. TCG Crossover Management LLC acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at approximately $19,751,000. Orbimed Advisors LLC acquired a new position in RAPT Therapeutics during the fourth quarter valued at approximately $20,754,000. Foresite Capital Management VI LLC acquired a new position in shares of RAPT Therapeutics during the fourth quarter worth $19,750,000. Finally, RTW Investments LP acquired a new position in shares of RAPT Therapeutics during the fourth quarter worth $18,587,000. Institutional investors own 99.09% of the company's stock.
About RAPT Therapeutics
(
Get Free Report)
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Featured Articles

Before you consider RAPT Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RAPT Therapeutics wasn't on the list.
While RAPT Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.